On January 20, 2024, the board of directors of Alaunos Therapeutics, Inc. appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective January 20, 2024. Mr. Hogue will continue serving on the Board. Mr. Hogue, age 54, has worked for over 20 years in various roles on both the buy- and sell-side covering biotechnology and pharmaceutical equities.

Most recently, he founded Dune Lake Capital, a family office focused on the healthcare industry. Mr. Hogue spent almost eight years as a senior analyst at Discovery Capital Management, where he covered global healthcare stocks including US therapeutics, Japanese pharmaceuticals and European pharma and biotech. Early in his career, he worked as a research scientist and as a patent examiner at the US Patent and Trademark Office.

Mr. Hogue holds an MBA from Duke University, an MS in Biotechnology from Johns Hopkins University and a BS in Physics from James Madison University. Mr. Hogue has served on the Board since December 29, 2023.